IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
NDA FilingdarovasertibPositive
AI Analysis
Summary
IDEAYA Biosciences' darovasertib combination therapy met the primary endpoint in the OptimUM-02 registrational trial for metastatic uveal melanoma, with NDA filing underway under the real-time oncology review program, expected to complete in H2 2026.
Clinical Trial Data
Phase
registrational
Primary Endpoint
Met
Outcome Details
OptimUM-02 trial met primary endpoint; NDA filing underway under RTOR program
Importance:8/10
Sentiment:
0.80
Phase_3oncologymelanomaNDA_filingregulatory_successRTOR
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 4, 2026 10:00 AM